Lantheus Holdings, Inc. Enters Agreement to Acquire Evergreen TheragnosticsOn January 27, 2025, Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that its subsidiary, Lantheus Medical Imaging, Inc., has entered into a definitive Agreement and Plan of

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lantheus’s 8K filing here.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.